{"ticker": {"uuid": "262c9900-58f8-4ceb-afad-47e61e23efc3", "symbol": "QNTM", "name": "Quantum BioPharma Ltd.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Quantum BioPharma Plans to Settle Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZ3F1WE1IZ3ZWcFc3RDdEMHFKTG9yZkk2MUFtYXhZc2phVlBUcFpMc0M0cVl4c1NNNDhzT1llVzJIYTF4NEdVejhseE0xVEoxMEk3YWRpT1RncEluOXVlUUFUOFJ3SXRNMmxnSlVveG5WdU1NMFRYMklXNGh1MHlRTVBzcmlrRjZQbi1pa2dYVkJjbnhKYmc?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-21T17:51:18+00:00", "published_display": "21 Jul 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPclhkV3BwOTRSYU5tWkJ0YTkxMmdBYVJyOVB6Y1hobFRCWmFfX1BmNm1XcWpNQnFVVWxuNkNlQlh6V0tnbl8yUjc5N2hkSURtc19TWl9jWVRWb2ZURVBRMW02eW8xTE1UTmZJc2Y2ZG44cEpJOU9Pd3VtS29XWTdTQ3JKSFNtcWd2akNKNWVfV1Z1N2JWRXNweEtqbTE5aENzSzI4TUFiTDdQMmVydGJmZ1diQkwtRlc3UzQ5SA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-20T23:10:00+00:00", "published_display": "20 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Announces Intention to Settle Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNF9IZlVPLS1FRGdrX1REM1J2ZlpzdDJZQkRJMzJ4UXJQZnlvZ2xwaElxa2oxSWFYSnQxLVV0TVlDNDBmaXNiNjFacExvNkc4d2Q4YnRtR2I4VzZtVFlGbzhLTVl5ZGdCcFhSd1ppNmdRbmhmeEY3QlVEcjV6cVhFaWVaVFRna1hCSkxhX0t0cWpVWG44T3RxSTRJLWpuTmFRSkl1MDdldjU?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-20T23:00:06+00:00", "published_display": "20 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-expands-clinical-184530119.html", "source_name": "NewMediaWire", "published_at": "2026-07-15T18:45:30+00:00", "published_display": "15 Jul 2026 18:45", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQT2MxLWQ2SzRsTEplaWN6bFRZdzVOb09weGdESnlYQ0Vra2tZVk9GT091YXVBODVBU01GdURmTWdrMjFEbHhwdmp2VkU3aEFGTE54eXljNFVKbm5WTVdCRGxOZTEzdDVNMWNiLW93dXdLTWpaamhlSGdUT1pfNTVlRkQ1czN1Q0NSNlc0SjJLdmVqQ0dLWndvRWw5R05OMFVBOUlybnMyb21XM2xqbzN0ME02VWZNVWRZbmlYSXJQVDRLZFNVNkV6X1JBaDJUcXlVRUpJRA?oc=5", "source_name": "Barchart.com", "published_at": "2026-07-15T16:56:17+00:00", "published_display": "15 Jul 2026 16:56", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Quantum BioPharma (QNTM) Is 'One to Watch'", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/why-quantum-biopharma-qntm-one-183000482.html", "source_name": "NewMediaWire", "published_at": "2026-07-10T18:30:00+00:00", "published_display": "10 Jul 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is \u2018One to Watch\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNUTR3bzdYTHpYRE93andBVE45MnlFZHJJTzhDM240eEhRNU9LQjY4SFV5UVo1NjRUSmFNNm40S0NHMTM0b1JiN214Rm1SWDVMellsVkk1ekZCYTNBLUk4NXgxZWVYR2lVeG5mSXlHeGRpTDF6SUFRYXJTbjI5QVIyb1hNOVhiMlJmdnp6Nk1EZUNDUUdtd3d3SkphUVZTVXRNYk1Pdg?oc=5", "source_name": "Barchart.com", "published_at": "2026-07-10T17:06:35+00:00", "published_display": "10 Jul 2026 17:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AdvisorShares Trust holds 203,564 Class B shares in Quantum Biopharma (QNTM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcTBqMGdHcmc1NmN4Qlk0Y0dBbTFRSVlLV1g1TTdGckhmbjk3NTc3LXl6aUxMdjl4M24xWXpsT1doV2xlMGlmbmVxZV9jOGcweld1Y3Zld211ZGY3V09mN2xURm5nVjJwRU51SDE5RkJKbUQ4Y0xrdUtERmhQTU5VXy1mZHhXVDdDRlh5ek8zeF9SR0xXaVZBSUVCRmtXSndMYTZ1V3ZyQ1h5M1FyajM5NDhFRHM4Z2c1NXdjMFZVTEtiMFR5SDV3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T21:21:39+00:00", "published_display": "08 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-showcases-unique-190000006.html", "source_name": "NewMediaWire", "published_at": "2026-07-01T19:00:00+00:00", "published_display": "01 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-reaches-key-193000702.html", "source_name": "NewMediaWire", "published_at": "2026-06-29T19:30:00+00:00", "published_display": "29 Jun 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-ltd-nasdaq-qntm-123000017.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T12:30:00+00:00", "published_display": "25 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-advances-novel-194500605.html", "source_name": "NewMediaWire", "published_at": "2026-06-23T19:45:00+00:00", "published_display": "23 Jun 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-ltd-nasdaq-qntm-123000330.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:30:00+00:00", "published_display": "23 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma\u2019s MS drug heads for phase 2 trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdjFRdUFVTUg0cEJfb3JKbGs1X1NkNGpSN2s5Yk5ncGhQQWVscl9fbzQwS2QwejJVU1ZUd2NxVDJqemh4M3VGREVzdzJzRGJKWVU4MWFINTBITFNwYThXZTd0N2JjNV9lMFU4eTFlOUlCWVhfVFlsMEJ0QlhqcENhUlQxLXJPajhhYXMzcVNneEJMNk9fZjhpeVpId3g3RDBzLWh0RDVIQ0s5X2Z5MVdOcksxZlBVYkppSXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd.", "summary": "Quantum BioPharma Ltd. (NASDAQ: QNTM) is a biopharmaceutical company focusing on treatments for neurodegenerative, metabolic, and alcohol misuse disorders. The company has a lead compound, Lucid-MS, for multiple sclerosis, and has spun out its unbuzzd\u2122 OTC product to Unbuzzd Well", "url": "https://thecse.com/listings/quantum-biopharma-ltd/", "source_name": "The Canadian Securities Exchange (CSE)", "published_at": "2026-06-05T11:39:34", "published_display": "05 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Engages Stocks.news For Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxPcmhVNWlwOWxkNlNuYjFSenBDLTR5ZVY0TnRxVkQzTU1DZmFMQjNQXzNVWUVhdW1lVGxlYVZkb2I0WGtBUi1pMmpMSHBDbmw4djNISl9iYTJxbl90TUFLOVZrQ19SclpyNUZ3TWFZcDRFN0Fndko1VDJUM3pRVUFSU1RGUUh5Y2pnU0NadHNpMzQybTMyT1ZCaG9FVEhMSHNoR0k4Q0RQN2lSeDl5cTg5Njh5cHdiNjBMeDBoUnI0MEg1OVZUQ0swMlJIVFlQTC0wZzlJMVd6WW56RklyV1JyXzJLX1gzTDctZkE5emhPYWk0R0dPUl9sSXhpSkJ6ZHNDMVl2dVNlQkZnSVdsN0E?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Provides Update on FDA Clinical Hold for Lucid-MS Drug Candidate | QNTM Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQWmgyTy1sR29RN2JYZG5kWHB6SDlzOHo5NzVubGdvR1BWTUdQNmxyU0RWcVVkcXN3TW8xRnphTUowSm5yanJHX0J3TnNBRzVLeUx2bXFDWkNSaXNqMjNVWWtfSjI2TjlFNkpWY2djX3Zsdmxvd2ZMdm0tbUVXTzMxLUhuNlJIak0wMkxOTWl3S0FFWDZGTm4yamtPUEVwQlV0NGZCcnVBQXhkbWY3TEFFREVaQUlHUGIwcHZzRw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Momentum Surges Amid MS Resarch Update - Quantum BioPharma (NASDAQ:QNTM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTGY5ampSc3QzWFFrTVN6bVFGT1VNSVpwek1Qd2RwTTVzNGlDcjNoanVmZGNLOTlkaGh5ZFBmckR2Q1JUT3NPa2RocDNJUTNWalQ2U3RoWU83MVJIOUFwaGc0bGY4dXlXVklBRjU3UnpodnFKUGN1MV9VLVNOTzF2cWo0Y2xYUlNnbVdSXzFLVjJJcTRhNk9LYmJHU0RpVVJRc0xoTl9zaVBOR0g1cUlGR3E3YXFMSzNLeFdRSkNxU01pLUw4NUlNSzhWUGwxVVJs?oc=5", "source_name": "Benzinga", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma stock surges on MS imaging study progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQR3dFcEZrQ1JUdVFLTk5mcnhMV1NqNEV2WUhoNU5QU0V4WEtJbjB3LXNYeEc0di1oZXoxaFJyS0VMdWRrZUFXa3ZOenhxaXpOTUdUdkhuRFVVeGhIU0Z3dW53QVFnSEFaV29WUG9pMVJSTzJrcm52NXRjSUxtWmotRW9pa3d4b2QxZ0kyLVlFMUNnd25jYS1HVUl5aGduNlZxRzdIam9iVHZTcFhhS1l3TTA2UEVEQVRfc2w3bFNB?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNaDhMazRVSTRKRFFKaVJwMEUzcGNnSHE5bV9PaURvWVFQNUwyQl9ZZkdBNFBXZGVpMF9NMldTcTRiSjhqbzhiaHhaZ1dQdGhaYUtGazFmSzlZd3Yway1xcHRzOThlMFFNQlJPUFhsZkFnQ0dCaUF4N3p0N000UkVXcUYwckZkSUJfaXNZS3NXOVVmZFhRVG9GSlhrel91NF9rUjk3WS1yZXlaX2FD?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "HUGE Stock: From FSD Pharma to Quantum BioPharma (QNTM)", "summary": "The article details the rebranding of FSD Pharma Inc. to Quantum BioPharma Ltd. in August 2024, changing its stock ticker from HUGE to QNTM on NASDAQ and CSE. This transition, accompanied by a 65:1 reverse stock split, reflects the company's refined focus on neurodegenerative and", "url": "https://www.bitget.com/wiki/huge-stock", "source_name": "Bitget", "published_at": "2026-05-04T17:39:14", "published_display": "04 May 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQWGtfRjd6TFVjQUV1SmtWbzZkNnlTalU4Mll1MllHLVVDdjRfZWNiaVExN2FuaGhETU1tTElLTC1NQWZDWi13T2FFS1BFY0EwM1VaVmhDZllMbUZlNmhzOHZHNWdKX1hocUIyT1FNSHRPOTBibHFxRkEycVZaZUw4TEI2QXRSTGxIRGFnakc0a1MtOXd4ajlWdGljeHFienRhOTc4SU4yYkpJUWxiOE82eklDQjFBUVMtY2ZDMzdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPai1tR1ctMHpVQ3Y4TUd0cFIzU1hjUGdOTGVXRWJramFIN1M1OXpweVJXR1dqUjZtZF92WjdJaFdIcDRJaTR3OFBzbnlRQ0FCdmE2M0FoNEVxbnpJOC1wR21pMkNlQWV0X1VjbnlZcmgyUlhKcjdySHdDUEFDeE4wM0ZwZ09KRjlRaG9JXzYxcUZySnRRUjBiTWc5ZTdqcTlmcjVDNmdzQkV3YnFGVUQyQV8wX1dCUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Quantum BioPharma Provides Corporate Update", "summary": "Quantum BioPharma has revised the terms of its Debenture Units due to a decrease in the public market price of its Class B subordinate voting shares. The conversion price per share has been reduced to $3.00, the number of Warrants per Debenture Unit increased to 333.33, and the e", "url": "https://www.globenewswire.com/news-release/2026/03/11/3254229/0/en/quantum-biopharma-provides-corporate-update.html", "source_name": "GlobeNewswire", "published_at": "2026-03-11T19:11:45", "published_display": "11 Mar 2026 19:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. to Release Financial Results and Announce Private Placement Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSDI2N2VhU3R0M2xlNjNIcHB5Qk52MGwzNTZDeDF6V1ZaUXQ5WUNBWVBlYzFsWDgwaDNfZ0pKRjM3dXg5aFZHbFRNWnhSazJETk5XSkdyYzRVVTdJQ0ZETVlJcTVpeUJsYlVycjR6VWdpQlRIRHBwSUF4cUs3QnJGS190WDJPX3pPTVREODhoODRzSmh6S245R29XNllOOHdGa3Zib1hoS05GYkkxa1BWRTNBc1N2MG95cnNRNlI3dzBpdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares", "summary": "Grant & Eisenhofer has filed a class action lawsuit against CIBC and RBC on behalf of Quantum BioPharma shareholder Paul Durkacz, alleging stock market manipulation of Quantum BioPharma shares between January 6, 2021, and October 15, 2025. Quantum BioPharma plans to seek appointm", "url": "https://www.sahmcapital.com/news/content/world-renowned-law-firm-grant-eisenhofer-files-class-action-lawsuit-against-canadian-banks-cibc-and-rbc-alleging-illegal-stock-market-manipulation-of-quantum-biopharma-shares-2025-12-20", "source_name": "Sahm", "published_at": "2025-12-20T13:09:36", "published_display": "20 Dec 2025 13:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (NASDAQ: QNTM) ends $21,225,000 ATM, settles $260,000 debt", "summary": "Quantum BioPharma closed a non-brokered private placement on December 10, 2025, issuing 30 Class A shares for $750, with two related parties increasing their voting rights significantly. The company also terminated its $21,225,000 at-the-market sales agreement with H.C. Wainwrigh", "url": "https://www.stocktitan.net/news/QNTM/quantum-bio-pharma-announces-closing-of-private-placement-provides-dvqrkys044ic.html", "source_name": "Stock Titan", "published_at": "2025-12-10T22:32:36", "published_display": "10 Dec 2025 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum Biopharma\u2019s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxONVo3S0hPMzBGY0N3cDhQekNSbVZPY1NJTC04Q1AwLUFDMnVTV2ZkX3EyWU04X0RLbW51bEl0RVVJaFBwdzY4T2dtWGNBWjRSOWQ5c3gzS3BRRlVZY29LOHJVYnRhQUJRSmhfc1JjSHlLN1FRdFA5ZGFKU2lVQjdIaXR1UlpKZw?oc=5", "source_name": "Market source", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Announces Record Date for Distribution of Contingent Value Rights to Class B Subordinate Voting Shareholders", "summary": "Quantum BioPharma Ltd. has set October 27, 2025, as the record date for distributing contingent value rights (CVRs) to Class B Subordinate Voting Shareholders. These CVRs will entitle shareholders to a portion of net proceeds from the company's ongoing $700 million litigation aga", "url": "https://www.quiverquant.com/news/Quantum+BioPharma+Ltd.+Announces+Record+Date+for+Distribution+of+Contingent+Value+Rights+to+Class+B+Subordinate+Voting+Shareholders", "source_name": "Quiver Quantitative", "published_at": "2025-10-03T11:11:00", "published_display": "03 Oct 2025 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case", "summary": "Quantum BioPharma announced October 27, 2025, as the record date for distributing Contingent Value Rights (CVRs) to Class B Subordinate Voting Shares holders. These CVRs will entitle holders to a pro rata portion of 10% to 50% of the net proceeds from a legal action against CIBC ", "url": "https://www.globenewswire.com/news-release/2025/10/03/3160883/0/en/quantum-biopharma-announces-the-record-date-for-the-distribution-of-a-special-dividend-of-contingent-value-rights-cvrs-tied-to-the-future-litigation-settlement-proceeds-of-its-usd-.html", "source_name": "GlobeNewswire", "published_at": "2025-10-03T07:00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Announces Intention to Declare Special", "summary": "Quantum BioPharma (NASDAQ: QNTM) announced its intention to declare a special dividend of Contingent Value Rights (CVRs) to shareholders. These CVRs will entitle holders to a pro rata portion (10% to 50%) of net proceeds from its over $700 million lawsuit against CIBC World Marke", "url": "https://www.globenewswire.com/news-release/2025/06/13/3098927/0/en/Quantum-BioPharma-Announces-Intention-to-Declare-Special-Dividend-of-Contingent-Value-Rights-CVRs-Linked-to-Future-Litigation-Settlement-Proceeds.html", "source_name": "GlobeNewswire", "published_at": "2025-06-13T17:10:35", "published_display": "13 Jun 2025 17:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Shareholders to Get Up to 50% of $700M Potential Legal Settlement via Special Dividend", "summary": "Quantum BioPharma (NASDAQ: QNTM) announced it plans to issue special dividend Contingent Value Rights (CVRs) to Class B Subordinate Voting Shareholders, entitling them to 10-50% of net proceeds from a $700 million litigation against major banks for alleged stock price manipulatio", "url": "https://www.stocktitan.net/news/QNTM/quantum-bio-pharma-announces-intention-to-declare-special-dividend-xvulurnvbjkm.html", "source_name": "Stock Titan", "published_at": "2025-06-13T13:08:42", "published_display": "13 Jun 2025 13:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54TWd3R25YaVlqak4wbzJwRVRxaktiNmYtZUNLQzZUSmUxdUdzX2RDVG1vZk52UkF2Ym9qM1g4ZmMzMzhuZWhPTGJYX2w1QzVuUkhJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:27:19+00:00", "published_display": "24 Apr 2025 23:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wJBVV95cUxNNk5rZm1VeV91YV9aX1ppb0s4bkRhTTdfeklSODRGZFQ0TVZjblJkemhTd3lCbXNTZ1hTcFJwSnVoQW9NUzN6cHNEbU1wV3dxRFNxUWVHYzdTWTB3MDZlUWRwenJuN2RydWtmWmx4amFlRHNEbzdfdHoyc1ktN3VFcDVmQlFnaUVwZ3FnX29id1dOZ3JyMkJ6SG11ZGxuRnNVNzhhTEprdUFWNmpzWU8xWlJNb0RLcG9tVHR4S3lPM3NHZGJpMXpkdW92TWNBZzBoMTVtTVBHT3lqNWtHWTFFSE1hU04tQXNaUFl4dnBKNUZUSktUVFpSaFFOdGZxdEp6aHRKQ3hNNzFILTBwbzRLSlNsczkyVEROVDBScXk2ZVF4R2tnX0Z0bTNDTkdTSmFsbWVES1RyVXZqbU5IUDNtekJXVkpzR0tzUnNoR29xYlFVTEE4b0owNDl6aw?oc=5", "source_name": "TMX Newsfile", "published_at": "2024-10-21T13:32:50+00:00", "published_display": "21 Oct 2024 13:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma sues over alleged stock spoofing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVXNYV1BPM3FOaHlvcTBsM0VPWGQ1SWNtclA5YzVwT1k2dFFlblJhak5hYkh5MlVLM1o3WDlpdXJVOWRicUdnSTBRYXlrOE5idzN1ZWlnbDMxLWRvcmtoUnRVTFV1bkNlVHA0S0FaX0w3VHJTZkNSYmpLa0djcFRBZzJ6cHduY2JycXExc3NvNWNwS2lKY1VCZUcwQ1pIc2QzM1E?oc=5", "source_name": "The Globe and Mail", "published_at": "2024-10-21T07:00:00+00:00", "published_display": "21 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update", "summary": "Quantum BioPharma Ltd. announced corporate updates including management changes, cancellation of 32,690 stock options, and the grant of 32,690 restricted share units (RSUs). The company also intends to settle $450,000 in bonuses for three executives into Class B Shares at a deeme", "url": "https://quantisnow.com/insight/quantum-biopharma-announces-intention-to-complete-debt-settlements-and-provides-corporate-update-5671091", "source_name": "Quantisnow", "published_at": "2024-08-23T19:30:00", "published_display": "23 Aug 2024 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Subordinate Voting Shares", "summary": "Quantum BioPharma Ltd., trading under QNTM, is a biopharmaceutical company focused on neurodegenerative and metabolic disorders, and alcohol misuse. The company has a lead compound, Lucid-MS, for multiple sclerosis, and has spun out an OTC product, unbuzzd\u2122, retaining a 20.10% ow", "url": "https://thecse.com/listings/quantum-biopharma-ltd-subordinate-voting-shares/", "source_name": "The Canadian Securities Exchange (CSE)", "published_at": "2024-08-15T22:39:07", "published_display": "15 Aug 2024 22:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5oZUdnVzY3bFhMbEg0Qk45YUdaQzJMQ29xT2tnYlVuVzRsRXo4TnRLOVZ0VnFpRlY4Z0Z0aG9wbkpXVFdYSGFsWFJwTWQyUQ?oc=5", "source_name": "Stock Titan", "published_at": "2024-08-15T10:03:45+00:00", "published_display": "15 Aug 2024 10:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QNTM Stock Price and Chart \u2014 CSE:QNTM", "summary": "This article provides a comprehensive overview of Quantum Biopharma Ltd. (CSE: QNTM) stock, including its current price, historical performance, key financial statistics, and upcoming earnings information. It also details the company's business segments, its focus on neurodegener", "url": "https://www.tradingview.com/symbols/CSE-QNTM/", "source_name": "TradingView", "published_at": "2024-08-15T04:43:02", "published_display": "15 Aug 2024 04:43", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM)", "summary": "This article provides a technical analysis of Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM), detailing indicators from moving averages, oscillators, and pivots. It offers a summary of signals (neutral, buy, sell) across various timeframes and explains the co", "url": "https://www.tradingview.com/symbols/CSE-QNTM/technicals/", "source_name": "TradingView", "published_at": "2024-08-15T01:40:45", "published_display": "15 Aug 2024 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contact - The Lethbridge Herald - News and Sports from around Lethbridge", "summary": "FSD Pharma Inc. (NASDAQ: HUGE) has announced plans for a share consolidation and a name change to Quantum BioPharma Ltd (QNTM). These actions, approved by shareholders, aim to help the company regain compliance with NASDAQ's minimum bid price and are awaiting NASDAQ approval to b", "url": "https://markets.financialcontent.com/lethbridgeherald/article/nnwire-2024-8-12-investornewsbreaks-fsd-pharma-inc-nasdaq-huge-cse-huge-fra-0k9a-shareholders-approve-plans-for-share-consolidation-name-change", "source_name": "FinancialContent", "published_at": "2024-08-12T09:14:00", "published_display": "12 Aug 2024 09:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Quantum BioPharma Plans to Settle Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZ3F1WE1IZ3ZWcFc3RDdEMHFKTG9yZkk2MUFtYXhZc2phVlBUcFpMc0M0cVl4c1NNNDhzT1llVzJIYTF4NEdVejhseE0xVEoxMEk3YWRpT1RncEluOXVlUUFUOFJ3SXRNMmxnSlVveG5WdU1NMFRYMklXNGh1MHlRTVBzcmlrRjZQbi1pa2dYVkJjbnhKYmc?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-21T17:51:18+00:00", "published_display": "21 Jul 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPclhkV3BwOTRSYU5tWkJ0YTkxMmdBYVJyOVB6Y1hobFRCWmFfX1BmNm1XcWpNQnFVVWxuNkNlQlh6V0tnbl8yUjc5N2hkSURtc19TWl9jWVRWb2ZURVBRMW02eW8xTE1UTmZJc2Y2ZG44cEpJOU9Pd3VtS29XWTdTQ3JKSFNtcWd2akNKNWVfV1Z1N2JWRXNweEtqbTE5aENzSzI4TUFiTDdQMmVydGJmZ1diQkwtRlc3UzQ5SA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-20T23:10:00+00:00", "published_display": "20 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Announces Intention to Settle Debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNF9IZlVPLS1FRGdrX1REM1J2ZlpzdDJZQkRJMzJ4UXJQZnlvZ2xwaElxa2oxSWFYSnQxLVV0TVlDNDBmaXNiNjFacExvNkc4d2Q4YnRtR2I4VzZtVFlGbzhLTVl5ZGdCcFhSd1ppNmdRbmhmeEY3QlVEcjV6cVhFaWVaVFRna1hCSkxhX0t0cWpVWG44T3RxSTRJLWpuTmFRSkl1MDdldjU?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-20T23:00:06+00:00", "published_display": "20 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-expands-clinical-184530119.html", "source_name": "NewMediaWire", "published_at": "2026-07-15T18:45:30+00:00", "published_display": "15 Jul 2026 18:45", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQT2MxLWQ2SzRsTEplaWN6bFRZdzVOb09weGdESnlYQ0Vra2tZVk9GT091YXVBODVBU01GdURmTWdrMjFEbHhwdmp2VkU3aEFGTE54eXljNFVKbm5WTVdCRGxOZTEzdDVNMWNiLW93dXdLTWpaamhlSGdUT1pfNTVlRkQ1czN1Q0NSNlc0SjJLdmVqQ0dLWndvRWw5R05OMFVBOUlybnMyb21XM2xqbzN0ME02VWZNVWRZbmlYSXJQVDRLZFNVNkV6X1JBaDJUcXlVRUpJRA?oc=5", "source_name": "Barchart.com", "published_at": "2026-07-15T16:56:17+00:00", "published_display": "15 Jul 2026 16:56", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Quantum BioPharma (QNTM) Is 'One to Watch'", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/why-quantum-biopharma-qntm-one-183000482.html", "source_name": "NewMediaWire", "published_at": "2026-07-10T18:30:00+00:00", "published_display": "10 Jul 2026 18:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Is \u2018One to Watch\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNUTR3bzdYTHpYRE93andBVE45MnlFZHJJTzhDM240eEhRNU9LQjY4SFV5UVo1NjRUSmFNNm40S0NHMTM0b1JiN214Rm1SWDVMellsVkk1ekZCYTNBLUk4NXgxZWVYR2lVeG5mSXlHeGRpTDF6SUFRYXJTbjI5QVIyb1hNOVhiMlJmdnp6Nk1EZUNDUUdtd3d3SkphUVZTVXRNYk1Pdg?oc=5", "source_name": "Barchart.com", "published_at": "2026-07-10T17:06:35+00:00", "published_display": "10 Jul 2026 17:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AdvisorShares Trust holds 203,564 Class B shares in Quantum Biopharma (QNTM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcTBqMGdHcmc1NmN4Qlk0Y0dBbTFRSVlLV1g1TTdGckhmbjk3NTc3LXl6aUxMdjl4M24xWXpsT1doV2xlMGlmbmVxZV9jOGcweld1Y3Zld211ZGY3V09mN2xURm5nVjJwRU51SDE5RkJKbUQ4Y0xrdUtERmhQTU5VXy1mZHhXVDdDRlh5ek8zeF9SR0xXaVZBSUVCRmtXSndMYTZ1V3ZyQ1h5M1FyajM5NDhFRHM4Z2c1NXdjMFZVTEtiMFR5SDV3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T21:21:39+00:00", "published_display": "08 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-showcases-unique-190000006.html", "source_name": "NewMediaWire", "published_at": "2026-07-01T19:00:00+00:00", "published_display": "01 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-reaches-key-193000702.html", "source_name": "NewMediaWire", "published_at": "2026-06-29T19:30:00+00:00", "published_display": "29 Jun 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-ltd-nasdaq-qntm-123000017.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T12:30:00+00:00", "published_display": "25 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-qntm-advances-novel-194500605.html", "source_name": "NewMediaWire", "published_at": "2026-06-23T19:45:00+00:00", "published_display": "23 Jun 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quantum-biopharma-ltd-nasdaq-qntm-123000330.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T12:30:00+00:00", "published_display": "23 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma\u2019s MS drug heads for phase 2 trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdjFRdUFVTUg0cEJfb3JKbGs1X1NkNGpSN2s5Yk5ncGhQQWVscl9fbzQwS2QwejJVU1ZUd2NxVDJqemh4M3VGREVzdzJzRGJKWVU4MWFINTBITFNwYThXZTd0N2JjNV9lMFU4eTFlOUlCWVhfVFlsMEJ0QlhqcENhUlQxLXJPajhhYXMzcVNneEJMNk9fZjhpeVpId3g3RDBzLWh0RDVIQ0s5X2Z5MVdOcksxZlBVYkppSXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd.", "summary": "Quantum BioPharma Ltd. (NASDAQ: QNTM) is a biopharmaceutical company focusing on treatments for neurodegenerative, metabolic, and alcohol misuse disorders. The company has a lead compound, Lucid-MS, for multiple sclerosis, and has spun out its unbuzzd\u2122 OTC product to Unbuzzd Well", "url": "https://thecse.com/listings/quantum-biopharma-ltd/", "source_name": "The Canadian Securities Exchange (CSE)", "published_at": "2026-06-05T11:39:34", "published_display": "05 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Engages Stocks.news For Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxPcmhVNWlwOWxkNlNuYjFSenBDLTR5ZVY0TnRxVkQzTU1DZmFMQjNQXzNVWUVhdW1lVGxlYVZkb2I0WGtBUi1pMmpMSHBDbmw4djNISl9iYTJxbl90TUFLOVZrQ19SclpyNUZ3TWFZcDRFN0Fndko1VDJUM3pRVUFSU1RGUUh5Y2pnU0NadHNpMzQybTMyT1ZCaG9FVEhMSHNoR0k4Q0RQN2lSeDl5cTg5Njh5cHdiNjBMeDBoUnI0MEg1OVZUQ0swMlJIVFlQTC0wZzlJMVd6WW56RklyV1JyXzJLX1gzTDctZkE5emhPYWk0R0dPUl9sSXhpSkJ6ZHNDMVl2dVNlQkZnSVdsN0E?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Provides Update on FDA Clinical Hold for Lucid-MS Drug Candidate | QNTM Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQWmgyTy1sR29RN2JYZG5kWHB6SDlzOHo5NzVubGdvR1BWTUdQNmxyU0RWcVVkcXN3TW8xRnphTUowSm5yanJHX0J3TnNBRzVLeUx2bXFDWkNSaXNqMjNVWWtfSjI2TjlFNkpWY2djX3Zsdmxvd2ZMdm0tbUVXTzMxLUhuNlJIak0wMkxOTWl3S0FFWDZGTm4yamtPUEVwQlV0NGZCcnVBQXhkbWY3TEFFREVaQUlHUGIwcHZzRw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Momentum Surges Amid MS Resarch Update - Quantum BioPharma (NASDAQ:QNTM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTGY5ampSc3QzWFFrTVN6bVFGT1VNSVpwek1Qd2RwTTVzNGlDcjNoanVmZGNLOTlkaGh5ZFBmckR2Q1JUT3NPa2RocDNJUTNWalQ2U3RoWU83MVJIOUFwaGc0bGY4dXlXVklBRjU3UnpodnFKUGN1MV9VLVNOTzF2cWo0Y2xYUlNnbVdSXzFLVjJJcTRhNk9LYmJHU0RpVVJRc0xoTl9zaVBOR0g1cUlGR3E3YXFMSzNLeFdRSkNxU01pLUw4NUlNSzhWUGwxVVJs?oc=5", "source_name": "Benzinga", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma stock surges on MS imaging study progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQR3dFcEZrQ1JUdVFLTk5mcnhMV1NqNEV2WUhoNU5QU0V4WEtJbjB3LXNYeEc0di1oZXoxaFJyS0VMdWRrZUFXa3ZOenhxaXpOTUdUdkhuRFVVeGhIU0Z3dW53QVFnSEFaV29WUG9pMVJSTzJrcm52NXRjSUxtWmotRW9pa3d4b2QxZ0kyLVlFMUNnd25jYS1HVUl5aGduNlZxRzdIam9iVHZTcFhhS1l3TTA2UEVEQVRfc2w3bFNB?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNaDhMazRVSTRKRFFKaVJwMEUzcGNnSHE5bV9PaURvWVFQNUwyQl9ZZkdBNFBXZGVpMF9NMldTcTRiSjhqbzhiaHhaZ1dQdGhaYUtGazFmSzlZd3Yway1xcHRzOThlMFFNQlJPUFhsZkFnQ0dCaUF4N3p0N000UkVXcUYwckZkSUJfaXNZS3NXOVVmZFhRVG9GSlhrel91NF9rUjk3WS1yZXlaX2FD?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HUGE Stock: From FSD Pharma to Quantum BioPharma (QNTM)", "summary": "The article details the rebranding of FSD Pharma Inc. to Quantum BioPharma Ltd. in August 2024, changing its stock ticker from HUGE to QNTM on NASDAQ and CSE. This transition, accompanied by a 65:1 reverse stock split, reflects the company's refined focus on neurodegenerative and", "url": "https://www.bitget.com/wiki/huge-stock", "source_name": "Bitget", "published_at": "2026-05-04T17:39:14", "published_display": "04 May 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQWGtfRjd6TFVjQUV1SmtWbzZkNnlTalU4Mll1MllHLVVDdjRfZWNiaVExN2FuaGhETU1tTElLTC1NQWZDWi13T2FFS1BFY0EwM1VaVmhDZllMbUZlNmhzOHZHNWdKX1hocUIyT1FNSHRPOTBibHFxRkEycVZaZUw4TEI2QXRSTGxIRGFnakc0a1MtOXd4ajlWdGljeHFienRhOTc4SU4yYkpJUWxiOE82eklDQjFBUVMtY2ZDMzdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPai1tR1ctMHpVQ3Y4TUd0cFIzU1hjUGdOTGVXRWJramFIN1M1OXpweVJXR1dqUjZtZF92WjdJaFdIcDRJaTR3OFBzbnlRQ0FCdmE2M0FoNEVxbnpJOC1wR21pMkNlQWV0X1VjbnlZcmgyUlhKcjdySHdDUEFDeE4wM0ZwZ09KRjlRaG9JXzYxcUZySnRRUjBiTWc5ZTdqcTlmcjVDNmdzQkV3YnFGVUQyQV8wX1dCUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Provides Corporate Update", "summary": "Quantum BioPharma has revised the terms of its Debenture Units due to a decrease in the public market price of its Class B subordinate voting shares. The conversion price per share has been reduced to $3.00, the number of Warrants per Debenture Unit increased to 333.33, and the e", "url": "https://www.globenewswire.com/news-release/2026/03/11/3254229/0/en/quantum-biopharma-provides-corporate-update.html", "source_name": "GlobeNewswire", "published_at": "2026-03-11T19:11:45", "published_display": "11 Mar 2026 19:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. to Release Financial Results and Announce Private Placement Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSDI2N2VhU3R0M2xlNjNIcHB5Qk52MGwzNTZDeDF6V1ZaUXQ5WUNBWVBlYzFsWDgwaDNfZ0pKRjM3dXg5aFZHbFRNWnhSazJETk5XSkdyYzRVVTdJQ0ZETVlJcTVpeUJsYlVycjR6VWdpQlRIRHBwSUF4cUs3QnJGS190WDJPX3pPTVREODhoODRzSmh6S245R29XNllOOHdGa3Zib1hoS05GYkkxa1BWRTNBc1N2MG95cnNRNlI3dzBpdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares", "summary": "Grant & Eisenhofer has filed a class action lawsuit against CIBC and RBC on behalf of Quantum BioPharma shareholder Paul Durkacz, alleging stock market manipulation of Quantum BioPharma shares between January 6, 2021, and October 15, 2025. Quantum BioPharma plans to seek appointm", "url": "https://www.sahmcapital.com/news/content/world-renowned-law-firm-grant-eisenhofer-files-class-action-lawsuit-against-canadian-banks-cibc-and-rbc-alleging-illegal-stock-market-manipulation-of-quantum-biopharma-shares-2025-12-20", "source_name": "Sahm", "published_at": "2025-12-20T13:09:36", "published_display": "20 Dec 2025 13:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (NASDAQ: QNTM) ends $21,225,000 ATM, settles $260,000 debt", "summary": "Quantum BioPharma closed a non-brokered private placement on December 10, 2025, issuing 30 Class A shares for $750, with two related parties increasing their voting rights significantly. The company also terminated its $21,225,000 at-the-market sales agreement with H.C. Wainwrigh", "url": "https://www.stocktitan.net/news/QNTM/quantum-bio-pharma-announces-closing-of-private-placement-provides-dvqrkys044ic.html", "source_name": "Stock Titan", "published_at": "2025-12-10T22:32:36", "published_display": "10 Dec 2025 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum Biopharma\u2019s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxONVo3S0hPMzBGY0N3cDhQekNSbVZPY1NJTC04Q1AwLUFDMnVTV2ZkX3EyWU04X0RLbW51bEl0RVVJaFBwdzY4T2dtWGNBWjRSOWQ5c3gzS3BRRlVZY29LOHJVYnRhQUJRSmhfc1JjSHlLN1FRdFA5ZGFKU2lVQjdIaXR1UlpKZw?oc=5", "source_name": "Market source", "published_at": "2025-11-25T08:00:00+00:00", "published_display": "25 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Announces Record Date for Distribution of Contingent Value Rights to Class B Subordinate Voting Shareholders", "summary": "Quantum BioPharma Ltd. has set October 27, 2025, as the record date for distributing contingent value rights (CVRs) to Class B Subordinate Voting Shareholders. These CVRs will entitle shareholders to a portion of net proceeds from the company's ongoing $700 million litigation aga", "url": "https://www.quiverquant.com/news/Quantum+BioPharma+Ltd.+Announces+Record+Date+for+Distribution+of+Contingent+Value+Rights+to+Class+B+Subordinate+Voting+Shareholders", "source_name": "Quiver Quantitative", "published_at": "2025-10-03T11:11:00", "published_display": "03 Oct 2025 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case", "summary": "Quantum BioPharma announced October 27, 2025, as the record date for distributing Contingent Value Rights (CVRs) to Class B Subordinate Voting Shares holders. These CVRs will entitle holders to a pro rata portion of 10% to 50% of the net proceeds from a legal action against CIBC ", "url": "https://www.globenewswire.com/news-release/2025/10/03/3160883/0/en/quantum-biopharma-announces-the-record-date-for-the-distribution-of-a-special-dividend-of-contingent-value-rights-cvrs-tied-to-the-future-litigation-settlement-proceeds-of-its-usd-.html", "source_name": "GlobeNewswire", "published_at": "2025-10-03T07:00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Announces Intention to Declare Special", "summary": "Quantum BioPharma (NASDAQ: QNTM) announced its intention to declare a special dividend of Contingent Value Rights (CVRs) to shareholders. These CVRs will entitle holders to a pro rata portion (10% to 50%) of net proceeds from its over $700 million lawsuit against CIBC World Marke", "url": "https://www.globenewswire.com/news-release/2025/06/13/3098927/0/en/Quantum-BioPharma-Announces-Intention-to-Declare-Special-Dividend-of-Contingent-Value-Rights-CVRs-Linked-to-Future-Litigation-Settlement-Proceeds.html", "source_name": "GlobeNewswire", "published_at": "2025-06-13T17:10:35", "published_display": "13 Jun 2025 17:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Shareholders to Get Up to 50% of $700M Potential Legal Settlement via Special Dividend", "summary": "Quantum BioPharma (NASDAQ: QNTM) announced it plans to issue special dividend Contingent Value Rights (CVRs) to Class B Subordinate Voting Shareholders, entitling them to 10-50% of net proceeds from a $700 million litigation against major banks for alleged stock price manipulatio", "url": "https://www.stocktitan.net/news/QNTM/quantum-bio-pharma-announces-intention-to-declare-special-dividend-xvulurnvbjkm.html", "source_name": "Stock Titan", "published_at": "2025-06-13T13:08:42", "published_display": "13 Jun 2025 13:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54TWd3R25YaVlqak4wbzJwRVRxaktiNmYtZUNLQzZUSmUxdUdzX2RDVG1vZk52UkF2Ym9qM1g4ZmMzMzhuZWhPTGJYX2w1QzVuUkhJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:27:19+00:00", "published_display": "24 Apr 2025 23:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wJBVV95cUxNNk5rZm1VeV91YV9aX1ppb0s4bkRhTTdfeklSODRGZFQ0TVZjblJkemhTd3lCbXNTZ1hTcFJwSnVoQW9NUzN6cHNEbU1wV3dxRFNxUWVHYzdTWTB3MDZlUWRwenJuN2RydWtmWmx4amFlRHNEbzdfdHoyc1ktN3VFcDVmQlFnaUVwZ3FnX29id1dOZ3JyMkJ6SG11ZGxuRnNVNzhhTEprdUFWNmpzWU8xWlJNb0RLcG9tVHR4S3lPM3NHZGJpMXpkdW92TWNBZzBoMTVtTVBHT3lqNWtHWTFFSE1hU04tQXNaUFl4dnBKNUZUSktUVFpSaFFOdGZxdEp6aHRKQ3hNNzFILTBwbzRLSlNsczkyVEROVDBScXk2ZVF4R2tnX0Z0bTNDTkdTSmFsbWVES1RyVXZqbU5IUDNtekJXVkpzR0tzUnNoR29xYlFVTEE4b0owNDl6aw?oc=5", "source_name": "TMX Newsfile", "published_at": "2024-10-21T13:32:50+00:00", "published_display": "21 Oct 2024 13:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma sues over alleged stock spoofing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVXNYV1BPM3FOaHlvcTBsM0VPWGQ1SWNtclA5YzVwT1k2dFFlblJhak5hYkh5MlVLM1o3WDlpdXJVOWRicUdnSTBRYXlrOE5idzN1ZWlnbDMxLWRvcmtoUnRVTFV1bkNlVHA0S0FaX0w3VHJTZkNSYmpLa0djcFRBZzJ6cHduY2JycXExc3NvNWNwS2lKY1VCZUcwQ1pIc2QzM1E?oc=5", "source_name": "The Globe and Mail", "published_at": "2024-10-21T07:00:00+00:00", "published_display": "21 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update", "summary": "Quantum BioPharma Ltd. announced corporate updates including management changes, cancellation of 32,690 stock options, and the grant of 32,690 restricted share units (RSUs). The company also intends to settle $450,000 in bonuses for three executives into Class B Shares at a deeme", "url": "https://quantisnow.com/insight/quantum-biopharma-announces-intention-to-complete-debt-settlements-and-provides-corporate-update-5671091", "source_name": "Quantisnow", "published_at": "2024-08-23T19:30:00", "published_display": "23 Aug 2024 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma Ltd. Subordinate Voting Shares", "summary": "Quantum BioPharma Ltd., trading under QNTM, is a biopharmaceutical company focused on neurodegenerative and metabolic disorders, and alcohol misuse. The company has a lead compound, Lucid-MS, for multiple sclerosis, and has spun out an OTC product, unbuzzd\u2122, retaining a 20.10% ow", "url": "https://thecse.com/listings/quantum-biopharma-ltd-subordinate-voting-shares/", "source_name": "The Canadian Securities Exchange (CSE)", "published_at": "2024-08-15T22:39:07", "published_display": "15 Aug 2024 22:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quantum BioPharma (QNTM) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5oZUdnVzY3bFhMbEg0Qk45YUdaQzJMQ29xT2tnYlVuVzRsRXo4TnRLOVZ0VnFpRlY4Z0Z0aG9wbkpXVFdYSGFsWFJwTWQyUQ?oc=5", "source_name": "Stock Titan", "published_at": "2024-08-15T10:03:45+00:00", "published_display": "15 Aug 2024 10:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QNTM Stock Price and Chart \u2014 CSE:QNTM", "summary": "This article provides a comprehensive overview of Quantum Biopharma Ltd. (CSE: QNTM) stock, including its current price, historical performance, key financial statistics, and upcoming earnings information. It also details the company's business segments, its focus on neurodegener", "url": "https://www.tradingview.com/symbols/CSE-QNTM/", "source_name": "TradingView", "published_at": "2024-08-15T04:43:02", "published_display": "15 Aug 2024 04:43", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM)", "summary": "This article provides a technical analysis of Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM), detailing indicators from moving averages, oscillators, and pivots. It offers a summary of signals (neutral, buy, sell) across various timeframes and explains the co", "url": "https://www.tradingview.com/symbols/CSE-QNTM/technicals/", "source_name": "TradingView", "published_at": "2024-08-15T01:40:45", "published_display": "15 Aug 2024 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contact - The Lethbridge Herald - News and Sports from around Lethbridge", "summary": "FSD Pharma Inc. (NASDAQ: HUGE) has announced plans for a share consolidation and a name change to Quantum BioPharma Ltd (QNTM). These actions, approved by shareholders, aim to help the company regain compliance with NASDAQ's minimum bid price and are awaiting NASDAQ approval to b", "url": "https://markets.financialcontent.com/lethbridgeherald/article/nnwire-2024-8-12-investornewsbreaks-fsd-pharma-inc-nasdaq-huge-cse-huge-fra-0k9a-shareholders-approve-plans-for-share-consolidation-name-change", "source_name": "FinancialContent", "published_at": "2024-08-12T09:14:00", "published_display": "12 Aug 2024 09:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 50, "sentiment_summary": {"positive": 11, "negative": 6, "neutral": 33, "score": 52, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.75, "count": 5}, {"event": "capital_return", "label": "Capital return", "weight": 1.65, "count": 3}], "positive_events": 11, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 3.24, "latest_week": "2026-07-17", "one_week_move": -2.1, "four_week_move": -14.7, "twelve_week_move": -10.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.119885, "market_dynamics_buy_signal": false, "relative_strength": -69.199506, "fair_value_gap": -86.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 30.9503, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.1% over one week, -14.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "NewMediaWire", "count": 5}, {"label": "Quiver Quantitative", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "marketscreener.com", "count": 2}, {"label": "Barchart.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 7}, {"label": "Balance sheet", "count": 5}, {"label": "Capital return", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.1% over one week, -14.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Quantum BioPharma Plans to Settle Debt"}], "updated_at": "2026-07-22T06:46:37.014849+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}